Trials / Completed
CompletedNCT01260545
Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
Phase I Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety and tolerability of CA-18C3 in subjects with hematologic malignancies, as well as look at the preliminary efficacy of IL-1alpha blockade.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CA-18C3 | 2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs. |
Timeline
- Start date
- 2011-04-30
- Primary completion
- 2012-06-30
- Completion
- 2012-09-30
- First posted
- 2010-12-15
- Last updated
- 2021-02-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01260545. Inclusion in this directory is not an endorsement.